Skip to main content

Rare Conditions: Medical Treatments

Volume 498: debated on Monday 26 October 2009

To ask the Secretary of State for Health what recent assessment he has made of the impact of the National Institute for Health and Clinical Excellence’s end-of-life criteria on patient access to treatments for rare conditions aimed at extending life; and if he will make a statement. (295041)

We have made no such assessment. The application of the explicit end-of-life flexibilities to individual appraisals is a matter for the National Institute for Health and Clinical Excellence (NICE) as an independent body.

The application of this flexibility, along with patient access schemes, have resulted in positive NICE guidance on a number of treatments including Sutent for renal cell carcinoma and Revlimid for multiple myeloma.